Table 3.
Increase in sensitivity to antibiotic resistance due to 13-o-MBB and its regioisomers.
| Drug | MIC in the Presence of Berberine Derivative (µg/mL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PAGUg1927 | PAGUg1931 | |||||||||
| Ber | 13-o-MBB | 13−m−MBB | 13−p−MBB | − | Ber | 13-o-MBB | 13−m−MBB | 13−p−MBB | − | |
| AMK | 4 | 2 | 4 | 4 | 8 | 1 | 0.5 | 0.5 | 0.5 | 1 |
| TOB | 0.25 | 0.5 | 0.5 | 0.5 | 0.5 | 0.25 | 0.25 | 0.5 | 0.125 | 0.25 |
| KM | 128 | 64 | 256 | 256 | 512 | 64 | 32 | 32 | 64 | 64 |
| SPCM | 256 | 64 | 128 | 128 | 1024 | 64 | 8 | 8 | 32 | 64 |
| NLFX | 0.25 | 0.0625 | 1 | 1 | 1 | 0.015625 | 0.015625 | 0.015625 | 0.015625 | 0.015625 |
| EM | 128 | 64 | 512 | 256 | 512 | 16 | 16 | 16 | 8 | 16 |
| CBPC | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EtBr | 512 | 128 | 256 | 256 | 256 | 64 | 8 | 8 | 16 | 64 |
| Tc | 2 | 1 | 8 | 8 | 16 | 0.125 | 0.125 | 0.125 | 0.125 | 0.25 |
| Cp | 4 | 2 | 8 | 8 | 8 | 2 | 2 | 2 | 1 | 2 |
| AZM | 64 | 64 | 256 | 256 | 512 | 8 | 8 | 8 | 4 | 8 |
| CEF | 1 | 0.25 | 0.125 | 2 | 8 | 0.0625 | 0.125 | 0.125 | 0.125 | 0.125 |
Note: Ber, combined berberine 256 µg/mL; 13-o-MBB, combined 13-o-MBB 128 µg/mL; 13−m−MBB, combined 13−m−MBB 64 µg/mL; 13−p−MBB, combined 13−p−MBB 64 µg/mL; AMK, amikacin; TOB, tobramycin; KM, kanamycin; SPCM, spectinomycin; NLFX, norfloxacin; EM, erythromycin; CBPC, carbenicillin; EtBr, ethidium bromide; Tc, tetracycline; Cp, chloramphenicol; AZM, azithromycin; CEF, cefepime.